EP1815877B1 - Hydrogel pour le traitment de blessures - Google Patents

Hydrogel pour le traitment de blessures Download PDF

Info

Publication number
EP1815877B1
EP1815877B1 EP06002149A EP06002149A EP1815877B1 EP 1815877 B1 EP1815877 B1 EP 1815877B1 EP 06002149 A EP06002149 A EP 06002149A EP 06002149 A EP06002149 A EP 06002149A EP 1815877 B1 EP1815877 B1 EP 1815877B1
Authority
EP
European Patent Office
Prior art keywords
preparation
use according
gel
liquid
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06002149A
Other languages
German (de)
English (en)
Other versions
EP1815877A1 (fr
Inventor
Sabine Scherer
Christian Wagner
Christian Dr. Leuner
Wolfgang Dr. Fleischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE602006010656T priority Critical patent/DE602006010656D1/de
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to EP06002149A priority patent/EP1815877B1/fr
Priority to AT06002149T priority patent/ATE449617T1/de
Priority to CA2640267A priority patent/CA2640267C/fr
Priority to US12/278,036 priority patent/US20090022780A1/en
Priority to PCT/EP2007/000824 priority patent/WO2007088038A1/fr
Priority to AU2007211617A priority patent/AU2007211617B2/en
Priority to JP2008552738A priority patent/JP5294876B2/ja
Publication of EP1815877A1 publication Critical patent/EP1815877A1/fr
Priority to IL192908A priority patent/IL192908A/en
Application granted granted Critical
Publication of EP1815877B1 publication Critical patent/EP1815877B1/fr
Priority to US13/733,829 priority patent/US20130122084A1/en
Priority to US14/057,995 priority patent/US9415133B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is related to gel preparations capable of absorbing as well as releasing liquid, and the use of such gel preparations in the treatment of wounds.
  • body tissue can have a variety of causes. Wounds can be caused e.g. by (mechanical) contact of weapons, tools, vehicles or other objects with the human or animal body. Furthermore, serious damage of the skin can also be caused by exposure to heat, cold or radiation as well as by contact with aggressive chemicals. Body tissue can of course be damaged or even destroyed by infective diseases, caused e.g. by microorganisms or viruses.
  • the body will generate new body tissue, as a main activity of the tissue repair process.
  • the generation of new body tissue may sometimes have a negative effect, e.g. if the repaired or re-grown tissue does not provide the same performance characteristics than the original tissue.
  • the negative effect can be solely cosmetic, in that the re-grown tissue or repaired tissue is functional, but perceived as disfiguring or unaesthetic. However, in more severe cases, the necessary functionality of the tissue may be impaired.
  • tissue repair can result in scar formation, which may lead to cosmetic problems, but may also render the affected body tissue less functional, e.g. less elastic.
  • This effect is not limited to the external skin of the human or animal body; scar tissue can also lead to reduced functionality of mucosa or other body tissue, including that of internal organs of the body.
  • tissue repair effects include hyperkeratosis and unregulated proliferation of tissue.
  • a moist wound healing environment has been shown to be often beneficial. It has been found that the survival of cells in a moist environment is improved, while a dry environment promotes the die back of cells.
  • ichor is formed, which serves to establish a liquid milieu.
  • the ichor contains components, like amino acids, electrolytes, etc., which support the cell metabolism and thus enhance wound healing.
  • eschar is generally formed to "seal" the wound.
  • a further benefit of a moist wound healing environment is that it also provides a better physiological basis for new cell growth.
  • Cell growth which is required for wound healing, is activated and the formation of new tissue is favored in the moist wound healing environment.
  • Some ichor formation is beneficial in this context.
  • the moist wound healing environment required for wound healing is improved in particular when the liquid content within the wound is optimized by suitable substances or preparations.
  • a typical known method to produce a moist wound healing environment is to use a topical gel, in particular a hydrogel, in a wound dressing.
  • a topical gel in particular a hydrogel
  • These gel wound dressings are especially useful as occlusive wound dressings.
  • the term "gel” always includes a hydrogel.
  • the known gels / hydrogels can be able to release liquid from the gel matrix, thus forming a suitable liquid reservoir for the wound environment.
  • gels are in general also capable of absorbing liquid, e.g. ichor, from the wound, if their liquid content can be further increased and may also by this fact provide for an improved wound healing environment.
  • Liquid generally means aqueous liquids, including liquids provided by the gel manufacturer or user (e.g. aqua dest., solutions of actives, suspensions and dispersions) and also including liquids produced by or in a wound (e.g. produced by the affected tissue).
  • liquids provided by the gel manufacturer or user (e.g. aqua dest., solutions of actives, suspensions and dispersions) and also including liquids produced by or in a wound (e.g. produced by the affected tissue).
  • “Liquid” includes liquid released by the gel and liquid (which may be different from such released liquid) reabsorbed from the wound.
  • hydrogels have an additional beneficial effect on the moist wound healing environment by "binding" certain compounds or contaminations into the gel, and thus improving the conditions for healing by removal of such materials from the wound.
  • a gel layer may "seal" the wound (without drying it) and thus enables easier dressing changes. If e.g. the dressing sticks to the wound, the wound may be newly injured when the dressing is removed. If a suitable gel is covering the wound, it is possible to change the dressing without reopening the already recovered wound, or causing new injuries.
  • gel-based wound healing preparations have been described.
  • various different types of gel-forming polymers have been used. These gel-forming polymers include e.g. carboxymethylcelluloses, modified starch and alginate polymers.
  • gels which are commercially available and can be applied in wound-healing include IntraSite® Gel (available from Smith & Nephew), Askina® Gel (available from Braun) and Varihesive® Gel (available from ConvaTec). These gels exhibit good liquid absorption capabilities. Their liquid release capabilities are, however, significantly lower than their liquid absorption capacities.
  • the known gels can contain various additional ingredients to adapt them for their intended use.
  • some of these gels comprise active agents to provide anti-inflammatory properties or the like.
  • Liposomes are highly suitable carriers for antiseptic agents, especially povidone iodine and provide an extended topical activity by interaction with cell surfaces.
  • Liposomes are well known drug or compound carriers and thus the application of medicaments in liposomal form has been the subject of investigation for quite some time.
  • An overview concerning the administration of compounds in liposomal form to the skin is e.g. provided by the review " Targeted delivery to the pilosebaceous unit via liposomes", Lauer et al. (1996), Advanced Drug Delivery Reviews, 18, 311 - 324 . This review describes the physico-chemical characterization of liposomal preparations and their therapeutic application for the treatment of the pilosebaceous unit.
  • Compounds that have been investigated for delivery by liposomes include e.g. anti-cancer agents, peptides, enzymes, anti-asthmatic and anti-allergic compounds and also antibiotics.
  • liposomal antiseptic preparations of povidone iodine can be used for the treatment of diseases of the upper and lower respiratory tract, as disclosed in WO 99/60998 and WO99/60999 .
  • Liposomal antiseptic preparations can be used for the treatment of herpes, acne and other specific diseases of the skin, as described in WO04/073720 , WO04/073682 and WO04/073683 .
  • WO 00/72822 discloses the use of liposomal preparations comprising anti-infective and/or anti-inflammatory agents for functional and cosmetic tissue remodeling and repair treatments.
  • US 2005/0214334 A1 discloses a polymerized hydrogel composition for hydrating or dehydrating a surface, the composition comprising a mixture of two polymerizable materials, a two-part redox catalyst system and a two-part polymerization medium.
  • the prior art still leaves a desire for optimization of the liquid content within the wound, in particular in balancing the liquid absorption and the liquid release properties of the gel-preparations.
  • the preparations according to the invention exhibit a surprisingly high capability to maintain a moisture level within the wound, which seems to be suitable to enhance wound healing.
  • the inventive preparations are able to release moisture or liquid from the gel to maintain a suitable moisture level within the wound, and in this capacity, the inventive preparations are superior to comparable known preparations.
  • the preparation according to the invention reveals a liquid release capability which is greater than its liquid absorption capability.
  • the liquid absorption capability of the inventive preparation is still suitable to absorb liquid from the wound, as necessary.
  • gel preparations which can comprise active agents, in particular anti-inflammatory agents, particulate carriers, in particular liposomes, film-forming substances or combinations thereof.
  • the present invention provides gel preparations which do not contain either active agents, particulate carriers, film-forming substances or combinations thereof.
  • the preparations according to the invention comprise at least one gel-forming polymer.
  • the gel-forming substance of the present invention can e.g. be selected from the group consisting of agar, alginates, alginic acids, Arabic gum, gelatine, starch, tragacanth gum, methylcelluloses, hydroxyethylcelluloses, carboxymethylcelluloses, polyacrylic acids and/or combinations thereof.
  • acrylic acid polymers are applied.
  • Polymers complying the USP Carbomer 940 monograph like Carbopol 908NF or Carbomer 940) are preferred from this group.
  • the gel-forming substances comprise polyacrylates, polymethacrylates, polyacrylic acids, polymethacrylic acids, polyvinylalcohols and combinations thereof. Polyacrylic acids are particularly preferred.
  • gel-forming substances are used in the form of hydrogels.
  • a hydrogel as used in the present invention, is a gel on the basis of a hydrophilic composition or compound, which is capable of absorbing and/or releasing a certain amount of liquid, in particular water.
  • the pH of the preparation according to the invention is preferably generally in the range from 3 to 7, more preferably from 4 to 6,5 and even more preferably in the range from 5 to 6.
  • the gel-forming substance is present in the preparation according to the invention at between about 0,1 % and about 10 %, preferably between about 0,5 % and about 5 %, more preferably between about 1,0% and about 3,0 %. All these percentages are wt.-%, based on total preparation weight.
  • the preparation of the invention further comprises at least one film-forming substance.
  • the addition of the film-forming substance may cause some loss of liquid release capability which may then outweigh the benefits provided by the gel in terms of increased moisture content. It is therefore preferred in some embodiments to provide inventive preparations without the addition of a film-forming substance.
  • the film forming substance of the present invention is a hyetellose, hypromellose, hyaluronate, polyvinylalcohol or polyvinylpyrrolidone.
  • a particular preferred film-forming substance is polyvinylpyrrolidone (PVP).
  • the film forming substance applied in the present invention is present in the range between 0,1 % to 10 %, preferably between 0,5 % and 7 %, more preferably between 1 % and 5 %, most preferably between 2 % and 4 %, based on the total weight of the preparation.
  • the preparation further comprises an active agent, in particular an anti-inflammatory agent.
  • Anti-inflammatory agents in accordance with the present invention broadly include antibiotic and antiviral preparations, and more specifically comprise antiseptic agents, antibiotic agents, corticosteroids and the like. Antiseptic agents are preferred.
  • antiseptic agents are understood to include those disinfecting agents which are pharmaceutically acceptable and suitable for the intended treatment.
  • Preferred antiseptic agents comprise oxygen- and halogen-releasing compounds, preferably iodine and iodine complexes, and/or metal compounds, preferably silver- and mercury-compounds.
  • Further antiseptic compounds comprise organic disinfectants, including formaldehyde-releasing compounds, phenolic compounds including alkyl- and aryl-phenolic compounds, chinolines and acridines, hexahydropyrimidines, quartenary ammonia compounds, imines and salts thereof and guanidines.
  • organic disinfectants including formaldehyde-releasing compounds, phenolic compounds including alkyl- and aryl-phenolic compounds, chinolines and acridines, hexahydropyrimidines, quartenary ammonia compounds, imines and salts thereof and guanidines.
  • the actives may advantageously be provided at concentrations only up to 90 %, only up to 75 %, sometimes only up to 50 % and in some preferred embodiments only up to 25 % of the concentrations known e.g. from comparable preparations in EP 0 639 373 (while in all these cases the concentration is non-zero and preferably at least 5 %, more often at least 10 % of those known from EP 0 639 373 ).
  • EP 0 639 373 uses PVP-iodine as a preferred active agent
  • other active agents other than PVP-iodine are used in specific preferred embodiments of the present invention.
  • particulate carriers, film-forming substances, active agents or combinations thereof may cause some loss of liquid release capability, it is specifically preferred in other embodiments, to omit either one of these ingredients particulate carriers, film-forming substances, active agents or combinations thereof.
  • a specifically preferred embodiment provides a preparations according to the invention which do not contain liposomes.
  • the inventive preparation is free of particulate carriers.
  • the preparation does not contain iodine as active agent.
  • the preparation is free of antiseptic agents.
  • the preparation according to the invention is free of anti-inflammatory agents .
  • the inventive preparations are free of active agents.
  • the preparation according to the invention is free of film-forming substances.
  • Free of antiseptic agent in the context of the present invention, means that the preparation does not comprise oxygen- and halogen-releasing compounds, preferably iodine and iodine complexes, and/or metal compounds, preferably silver- and mercury-compounds, organic disinfectants, including formaldehyde-releasing compounds, phenolic compounds including alkyl- and aryl-phenolic compounds, chinolines and acridines, hexahydropyrimidines, quartenary ammonia compounds, imines and salts thereof and guanidines.
  • oxygen- and halogen-releasing compounds preferably iodine and iodine complexes, and/or metal compounds, preferably silver- and mercury-compounds
  • organic disinfectants including formaldehyde-releasing compounds, phenolic compounds including alkyl- and aryl-phenolic compounds, chinolines and acridines, hexahydropyrimidines, quartenary ammonia compounds, imines and salts
  • inventive preparation does not contain antibiotic and antiviral preparations, antibiotic agents or corticosteroids.
  • Free of active pharmaceutically agents in the context of this invention means that the inventive preparation does not contain any pharmaceutically active agents.
  • the hydrogel itself is not covered by the term pharmaceutically active agent.
  • Free of particulate carrier means that the inventive preparation does not contain particulate carriers, especially not liposomes, microspheres, nanoparticles, or large porous particles
  • Free of film-forming substances means that the inventive preparation does not contain film-forming substances, especially not hyetellose, hypromellose, hyaluronate, polyvinylalcohol or polyvinylpyrrolidone.
  • the preparation according to the invention may comprise further additives and adjuvants such as conserving agents, antioxidants, consistency forming additives or pH-adjusting agents.
  • the preparations according to the invention can optionally comprise wound healing agents.
  • Suitable wound healing agents comprise e.g. dexpanthenol, allantoines, azulenes, tannins, vitamins (preferably vitamin B), and derivatives thereof.
  • the preparations according to the invention are capable of maintaining a level of moisture/liquid within the wound to an extent that wound healing is enhanced.
  • the level of moisture which an inventive preparation is capable to maintain in a wound can generally be measured by the capability to absorb a certain amount of liquid or to the ability to release liquid to a substrate and/or wound.
  • the liquid release properties of the preparations according to the invention are of particular interest in the context of the present invention.
  • the liquid affinity of hydrogel dressings is specified as the percentage of the capability to absorb or release liquids determined by the increase or decrease, respectively in gel weight.
  • the preparations according to the invention have been proven to be particularly suitable to release liquid or moisture, to wounds as well as test substrates.
  • the preparation releases at least 8 %, preferably at least 10 %, more preferably at least 12 %, at least 14%, at least 16 %, at least 18 %, at least 20 % or most preferably at least 25 % of the liquid from the test substrate under the test conditions of EN 13726-1:2002.
  • the liquid absorption, measured in gain of gel weight is less than 15 %, preferably less than 12 %, more preferably less than 10 %, less than 8 %, less than 6 %, less than 5 % and most preferably less than 4 % .
  • preparations according to the invention may be designed to provide varying liquid absorption and release properties, and that for this purpose, all combinations of values given in above ranges may be selected.
  • the liquid affinity of hydrogel dressings can be classified according to the percentage of the absorption or release of liquid.
  • a wound dressing which absorbs 0 to 10 % of its weight from Agar is classified as "type 1", greater than 10 to 20 % as “type 2", greater than 20 to 30 % as “type 3", greater than 30 to 40 % as “type 4" and greater than 40 to 50% as “type 5", respectively.
  • the liquid affinity with respect to the liquid release to gelatine which is measured by the decrease of the gel weight, is classified as follows: a liquid release in the range of 0 to 5 % as "type a”, greater than 5 % to 10 % as “type b”, greater than 10 % to 15 % as “type c”, greater than 15 % to 20 % as “type d”, greater than 20 % to 25 % as "type e”.
  • a wound dressing that absorbs about 25 % liquid, based on the original weight of the gel, from agar and hardly releases any liquid (less than 5 %) to gelatine is classified as a "3a type" wound dressing.
  • the preparation is classified as "type 1c", “type 1d”, “type 1e” or “type 2e”.
  • the preparation according to the invention can applied in pre-gel form at the desired locus, e.g. as a liquid.
  • the liquid preparation can easily be applied e.g. in form of a spray.
  • Such a liquid preparation can comprise water and/or any pharmaceutically acceptable solvent or any mixture of pharmaceutically acceptable solvents and water (water, as used anywhere in this specification includes all kinds of aqueous systems, like buffer solutions and the like).
  • the pharmaceutically acceptable solvent(s) comprises one or more organic solvent(s).
  • Volatile alcohol(s) are particularly preferred. Such alcohols are e.g. ethanol, n- propanol, i -proponal, and/or butanols and combinations of the afore-mentioned.
  • the pre-gel forming preparation Upon application of the pre-gel forming preparation at least one of the volatile components evaporates or is absorbed and forms gel preparations according to the invention.
  • Suitable pre-gels are e.g. disclosed in EP 0 704 206 .
  • the inventive preparations can be prepared by dispersing the gel-forming polymer in an amount of a suitable liquid or solvent, preferably water.
  • the preparations according to the invention comprise between about 0,1 g and about 10 g, preferably between about 0,5 g and about 5 g, more preferably between about 1,0 g and about 3,0 g gel-forming polymer per 100 g preparation.
  • the pH of the mixture can be adjusted by addition of a suitable acid or base, which are preferably added in solution, if necessary.
  • the pH of the final preparation is between about 3 and about 7, preferably between about 4 and about 6.5, more preferably between about 5 and about 6. If the desired conditions (pH-value, etc.) are met, the gel is allowed to swell for an appropriate period of time.
  • the film-forming substance can be present in the range between 0,1 g to 10 g, preferably between 0,5 g and 7 g, more preferably between 1 g and 5 g, most preferably between 2 g and 4 g, based on 100 g of the preparation.
  • the film-forming substance is generally provided in solution, but can also be provided in any other suitable form known to the person skilled in the art.
  • the film-forming substance is at first combined with the liposomal preparation and subsequently added to the formed gel. The resulting mixture can then be further processed, as necessary.
  • an active agent in particular an anti-inflammatory agent is comprised by the inventive preparation.
  • Some specifically preferred embodiments of the present invention comprise other active agents than PVP-iodine.
  • inventive preparation comprises further ingredients or adjuvants like conservatives, buffer solutions, etc.
  • skilled person is able to select and incorporate these substances into the preparations according to the invention for the intended use.
  • povidone iodine is exemplified and liposomes are chosen as the carrier.
  • the povione iodine can be omitted to provide embodiments of the present invention which do not comprise an active agent, in particular any antiseptic agent.
  • PVP-iodine can be substituted by another active agent, suitable for the intended use.
  • the exemplified embodiments serve to illustrate mutatis mutandis, the characteristics of inventive preparations which comprise neither actives nor particulate carrier materials.
  • particulate carriers such as "large porous particles” or other micelles, nanoparticles, etc. instead of the exemplified liposomes, can be formulated with active agents like PVP-iodine.
  • a Carbopol 980 NF composition was prepared. The amounts shown in Table I were used either for analytical or scale up compositions. Table I Pos. Substance Amount (g/100g) Scale up (kg/1000kg) A H 2 O 90,00 900,00 A Carbopol® 980 NF 1,50 15,00 B H 2 O 4,60 46,00 B NaOH solid 0,46 4,6 C H 2 O ad 100 ad 1000 Pos. stands for Position (see also below Table II). Carbopol 980 NF was purchased from BF Goodrich or Noveon.
  • a Carbopol 980NF composition was prepared. The amounts shown in Table III were used either for analytical or scale up compositions. Table III Pos. Substance Amount (g/100g) Scale up (kg/5000kg) A H 2 O 40,00 2000 A Germall II 0,30 15,00 B Carbopol 980 NF 1,50 75,0 C H 2 O 4,60 230,00 C NaOH solid 0,46 23,00 D H 2 O 48,00 2400 E H 2 O 3,00 150 E Na 2 (HPO 4 ) 0,225 11,25 E Citric acid 0,1065 5,33 F H 2 O ad 100 ad 5000 Pos. stands for Position (see also below Table IV). Carbopol 980NF was purchased from BF Goodrich.
  • a liposomal Carbopol 980NF composition was prepared. The amounts shown in Table V were used either for analytical or scale up compositions. Table V Pos. Substance Amount (g/100g) Scale up (kg/5000kg) A H 2 O 40,00 2000 A Germall II 0,30 15,00 B Carbopo1980NF 1,50 75,0 C H 2 O 4,60 230,0 C NaOH solid 0,46 23,00 D H 2 O 15,00 750 D Phospholipon 90 H 3,00 150 E H 2 O 27,50 1375 F H 2 O 2,50 125 G H 2 O 3,00 150 G Na 2 (HPO 4 ) 0,225 11,25 G Citric acid 0,1065 5,33 H H 2 O Ad 100 ad 5000 Pos. stands for Position (see also below Table V). Carbopol 980NF was purchased from BF Goodrich. Phospholipon 90 H was purchased from Rhone Poulene.
  • a liposomal Carbopol 980NF composition was prepared. The amounts shown in Table VII were used either for analytical or scale up compositions. Table VII Pos. Substance Amount (g/100g) Scale up (kg/5000kg) A H 2 O 40,00 2000 A Germall II 0,30 15,00 B Carbopo1980NF 1,50 75,0 C H 2 O 4,60 230,0 C NaOH solid 0,46 23,0 D H 2 O 15,00 750 D Phospholipon 90 H 3,00 150 E H 2 O 22,00 1100 E PVP (Kollidon 30) 3,00 150 F H 2 O 2,50 125 G H 2 O 2,50 125 H H 2 O 3,00 150 H Na 2 (HPO 4 ) 0,225 11,25 G Citric acid 0,1065 5,33 I H 2 O Ad 100 ad 5000 Pos. stands for Position (see also below Table VIII). Carbopol 980NF was purchased from BF Goodrich, Phospholipon 90 H was purchased from Rhone Poulene and PVP (Kollidon 30) from BASF.
  • a liposomal composition containing PVP-iodine as an active agent was prepared.
  • the amounts shown in Table IX were used either for analytical or scale up compositions.
  • Table IX Pos. Substance Amount (g/100g) Scale up (kg/1500kg) A H 2 O 15,0 200,0 A Phospolipon 90 H 3,0 45,0 B H 2 O 40,0 600,0 B Carbopol® 980 NF 1,5 22,5 C H 2 O 2,0 30,0 C KIO 3 0,0708 1,09 D H 2 O 20,0 300,0 D PVP-iodine 30/06 Available iodine (10%) 3,0 45,0 E H 2 O 2,5 50,0 F H 2 O 2,5 50,0 G H 2 O 4,6 69,0 G NaOH solid 0,46 6,9 I Citric acid, H 2 O free 0,1065 1,059 I Na 2 (HPO) 4 , H 2 O free 0,225 3,37 I H 2 O 3,0 45,0 H H 2 O Ad 100,0 ad 1500 Pos.
  • Phospholipon® 90 H was purchased from Aventis (Germany).
  • Carbopol® 980 NF was purchased from Noveon Inc. (USA) or Gattefossé (Germany) and PVP Iodine 30/06 was purchased from BASF (Germany).
  • H 2 O-temperature may be adjusted to anywhere between ambient temperature and 100 °C.
  • KIO 3 is not obligatory.
  • 3 Dissolve NaOH completely in H 2 O (Pos. G). NaOH is used in concentrations common for pharmaceutical preparations.
  • Other Bases or substances suggested by the supplier of the gel forming substances may also be used for formation of gel structure as e.g. KOH, Triethanol-amine, 2-Amino-2-methyl-1-propanol, tris(hydroacnemethyl)aminoethan, 2-hydroacnepropyl-ethylen-diamine, diisopropanolamine.
  • 4 Mix PVP-iodine into H 2 O while stirring at 1000 upm in conventional stirrer (Pos. D).
  • a complete dispersion has to be achieved.
  • Apparatus of the rotor/stator principle, high pressure homogenisators, ultrasound or extrusion technology may also be used for stirring.
  • the NaOH-solution No. 3
  • the gel is adjusted to a pH of 3.0 ( ⁇ 0,2). Further processing to a gel may be feasible without pH pre-adjustment and is dependent on the gel-forming substance 7
  • the KIO 3 solution (No.2) is added to the PVP-Iodine solution (No. 4) while stirring at 1000 upm. Reaction between KIO 3 and PVP-iodine is time dependent.
  • stirring time has to be adapted accordingly.
  • stirring time may be between 10 min and 2 h Stirring continued for at least 60 min.
  • the PVP-iodine- KIO 3 -solution is pumped into the liposomal dispersion (No. 5). Stirring time is variable depending on until when an homogeneous mixture has formed. Subsequently it is stirred for 30 min at 1000 upm.
  • the PVP-iodine- KIO 3 -liposomes- dispesion is added to the gel (No. 6). Stirring time is variable depending on until when an homogeneous mixture has formed. It is stirred for 30 min at 30 upm. Stirring time should be as short as possible so that gel structure gets not disrupted.
  • homogenization is performed by forced circulation pumping for 2 min at 2800 upm. After checking for agglomerates, it may be homogenized for further 1- 2 min. 10 Remove agglomerates if present. Adjust stirring time and speed to gel quality. Add 50,0 kg NaOH-solution (in the scale up, point 3) while stirring at 30 upm. Amounts of NaOH may vary. Adding of base by step wise adjustment until desired pH is achieved. Stir for further 30 min at 30 upm at ⁇ 30 °C. Cool if necessary. Determine pH and add additional NaOH until an pH of 5.5 ( ⁇ 0.2) is achieved. After each adding step stir for 20 min. After each adding step homogenize by circulation pressure pumping for 15 sec at 1000 upm.
  • Agar and gelatine which are used as test substrates were purchased from Merck.
  • the tests were performed according to test procedures for primary wound dressings.
  • Table XI Liquid affinity of Carbopol® 980 NF Gel (a): Sample Agar (absorption) liquid affinity gain of gel weight (%) Gelatine (release) liquid affinity loss of gel weight (%) 1 4 -18 2 4 -18 3 4 -18 4 4 -18 5 4 -19 Mean 4 -18 S rel 0 % 2,5 %
  • the inventive Carbopol® 980 NF gel (a) releases liquid very well, which is demonstrated by 18 % loss of gel weight.
  • the inventive gel exhibits a liquid absorption of 4 %.
  • the Carbopol® 980 NF gel a) is a "type 1d" gel by the standards of EN13726-1:2002.
  • Table XII Liquid affinity of liposomal Carbopol® 980 NF Gel
  • the liposomal Carbopol® NF980 gel (b) reveals good liquid release properties, which are at 17 % weight loss, only slightly lower than those of Carbopol® 980 NF preparation a).
  • the liquid absorption capacity is slightly increased in comparison to a) (see Table XI) and revealed 5 % liquid absorption.
  • the liposomal gel preparation b) can be classified as a "type 1d" by the standards of EN13726-1:2002.
  • Table XIII Liquid affinity of liposomal Carbopol® 980 NF Gel and PVP (c): Sample Agar (absorption) liquid affinity gain of gel weight (%) Gelatine (release) liquid affinity loss of gel weight (%) 1 9 -14 2 9 -14 3 8 -14 4 9 -14 5 8 -14 Mean 9 -14 S rel 6,4 % 0 %
  • the liquid release properties of the inventive liposomal gel (c) including PVP as a film-forming substance reveals a liquid release value of 14 % and an absorption capacity of 9 %.
  • the liposomal Carbopol® 980 NF Gel including PVP is a "type 1c" by the standards of EN13726-1:2002.
  • the Askina® Gel exhibits an liquid release of 3 %, which is significantly lower than in the examples a) to c) (see Tables XI to XIII). The liquid absorption is with 28 % higher than in the examples a) to c). Askina® Gel is classified as a "type 3a" by the standards of EN13726-1:2002.
  • Table XV Liquid affinity of IntraSite® Gel (e) Sample Agar (absorption) liquid affinity gain of gel weight (%) Gelatine (release) liquid affinity loss of gel weight (%) 1 15 -6 2 25 -7 3 13 -7 4 13 -7 5 15 -6 Mean 16 -7 S rel 31 % 8,3 %
  • the IntraSite® Gel releases 7 % of the liquid to the test substrate and showed a liquid absorption of 16 %.
  • the IntraSite® Gel has a lower liquid release capacity than the preparation according to the invention.
  • IntraSite® Gel is classified as a "type 2b" by the standards of EN 13726-1:2002.
  • Table XVI Liquid affinity of NU-Gel (f): Sample Agar (absorption) liquid affinity gain of gel weight (%) Gelatine (release) liquid affinity loss of gel weight (%) 1 29 -2 2 29 -4* 3 29 -2 4 29 -5* 5 29 -2 Mean 29 -2 S rel 0% 0% * Sample has not been used for further analysis (film broke)
  • the NU Gel exhibits only a very low liquid release of 2 %, while its liquid absorption is determined to be 29 %. NU Gel is classified as a "type 3a" by the standards of EN 13726-1:2002.
  • Table XVII Liquid affinity of Varihesive® Hydrogel (g): Sample Agar (absorption) liquid affinity gain of gel weight (%) Gelatine (release) liquid affinity loss of gel weight (%) 1 32 -6 2 32 -6 3 32 -6 4 32 -6 5 32 -6 Mean 32 -6 S rel 0 % 0 %
  • Varihesive® Hydrogel revealed a liquid release value of 6 %, which is significantly lower than the release capacity of the inventive preparations.
  • the liquid absorption is 32 %.
  • Varihesive® Hydrogel is classified as a "4b type" by the standards of EN13726-1:2002.
  • liquid affinity tests clearly demonstrates that the liquid release properties of the preparations according to the invention are significantly higher than the release characteristics of the known gels of the prior art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Colloid Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers & Plastics (AREA)

Claims (35)

  1. Utilisation d'un polymère conforme à la série Carbomer 940 de l'USP dans la fabrication d'un hydrogel pour le traitement des plaies ; dans laquelle l'hydrogel a une valeur pH comprise entre 4 et 6,5, et la capacité de la préparation hydrogel à libérer du liquide est supérieure à sa capacité à absorber du liquide, dans laquelle la préparation ne contient pas de liposomes.
  2. Utilisation selon la revendication 1, dans laquelle la préparation comprend en outre une substance filmogène.
  3. Utilisation selon la revendication 2, dans laquelle la substance filmogène est de l'hyétellose, de l'hypromellose, du hyaluronat, de l'alcool polyvinylique ou de la polyvinylpyrrolidone (PVP).
  4. Utilisation selon l'une quelconque des revendications 2 à 3, dans laquelle la substance filmogène est présente entre 0,1 % et 10 %, sur la base du poids total de la préparation.
  5. Utilisation selon l'une quelconque des revendications 2 à 4, dans laquelle la substance filmogène est la polyvinylpyrrolidone (PVP).
  6. Utilisation selon l'une quelconque des revendications précédentes, comprenant en outre au moins un agent antiseptique.
  7. Utilisation selon la revendication 6, dans laquelle l'agent antiseptique comprend des composés libérant de l'oxygène et de l'halogène, de préférence de l'iode et des complexes de l'iode, et/ou des composés du métal, de préférence des composés de l'argent et du mercure.
  8. Utilisation selon la revendication 6 ou 7, dans laquelle la préparation comprend en outre des composés antiseptiques tels que des désinfectants organiques, notamment des composés libérant du formaldéhyde, des composés phénoliques, notamment des composés alkylphénoliques et arylphénoliques, des chinolines et des acridines, des hexahydropyrimidines, des composés d'ammonium quaternaire, des imines et des sels de ceux-ci et des guanidines.
  9. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle la préparation comprend en outre des additifs et des adjuvants tels que des conservateurs, des anti-oxydants, des additifs de texture ou des tampons.
  10. Utilisation selon l'une quelconque des revendications précédentes, comprenant en outre un agent cicatrisant.
  11. Utilisation selon la revendication 10, dans lequel l'agent cicatrisant est choisi dans le groupe constitué par le dexpanthénol, les allantoïnes, les azulènes, les tannines et les vitamines.
  12. Utilisation selon l'une quelconque des revendications précédentes, comprenant en outre un milieu pharmaceutiquement acceptable approprié.
  13. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle la libération de liquide de la préparation est d'au moins 8 %, conformément à l'essai selon l'EN 13726-1:2002.
  14. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le gel absorbe moins de 15 %, conformément à l'essai selon l'EN 13726-1:2002.
  15. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle l'hydrogel est constitué d'un pré-gel sur l'emplacement souhaité par évaporation d'au moins un composant volatil et/ou par absorption d'un composant liquide par le tissu corporel.
  16. Utilisation selon la revendication 1, dans laquelle la préparation ne contient pas d'iode.
  17. Utilisation selon la revendication 16, dans laquelle la préparation est dépourvue d'excipients particulaires.
  18. Utilisation selon les revendications 16 et 17, dans laquelle la préparation est dépourvue d'agents antiseptiques.
  19. Utilisation selon l'une quelconque des revendications 16 à 18, dans laquelle la préparation est dépourvue d'agents anti-inflammatoires.
  20. Utilisation selon l'une quelconque des revendications 16 à 19, dans laquelle la préparation est dépourvue d'agents pharmaceutiquement actifs.
  21. Utilisation selon l'une quelconque des revendications 16 à 20, dans laquelle la préparation est dépourvue de substances filmogènes.
  22. Utilisation selon l'une quelconque des revendications 16 à 21, dans laquelle la préparation comprend en outre des additifs et des adjuvants tels que des conservateurs, des anti-oxydants, des additifs de texture ou des tampons.
  23. Utilisation selon l'une quelconque des revendications 16 à 22, dans laquelle la libération de liquide de la préparation est d'au moins 8 %, conformément à l'essai selon l'EN 13726-1:2002.
  24. Utilisation selon l'une quelconque des revendications 16 à 23, dans laquelle le gel absorbe moins de 15 %, conformément à l'essai selon l'EN 13726-1:2002.
  25. Utilisation selon l'une quelconque des revendications 16 à 24, dans laquelle l'hydrogel est constitué d'un pré-gel sur l'emplacement souhaité par évaporation d'au moins un composant volatil et/ou par absorption d'un composant liquide par le tissu corporel.
  26. Préparation cicatrisante comprenant un hydrogel comprenant un polymère conforme à la série Carbomer 940 de l'USP, dans laquelle l'hydrogel a une valeur pH comprise entre 4 et 6,5, et la capacité de la préparation à libérer du liquide est supérieure à sa capacité à absorber du liquide, et laquelle préparation ne contient ni liposomes ni iode.
  27. Préparation selon la revendication 26, laquelle préparation est dépourvue d'excipients particulaires.
  28. Préparation selon l'une quelconque des revendications 26 et 27, laquelle préparation est dépourvue d'agents antiseptiques.
  29. Préparation selon l'une quelconque des revendications 26 à 28, laquelle préparation est dépourvue d'agents anti-inflammatoires.
  30. Préparation selon l'une quelconque des revendications 26 à 29, laquelle préparation est dépourvue d'agents pharmaceutiquement actifs.
  31. Préparation selon l'une quelconque des revendications 26 à 30, laquelle préparation est dépourvue de substances filmogènes.
  32. Préparation selon l'une quelconque des revendications 26 à 31, laquelle préparation comprend en outre des additifs et des adjuvants tels que des conservateurs, des anti-oxydants, des additifs de texture ou des tampons.
  33. Préparation selon l'une quelconque des revendications 26 à 32, dans laquelle la libération de liquide de la préparation est d'au moins 8 %, conformément à l'essai selon l'EN 13726-1:2002.
  34. Préparation selon l'une quelconque des revendications 26 à 33, dans laquelle le gel absorbe moins de 15 %, conformément à l'essai selon l'EN 13726-1:2002.
  35. Pansement comprenant une préparation telle que définie dans l'une quelconque des revendications 26 à 34.
EP06002149A 2006-02-02 2006-02-02 Hydrogel pour le traitment de blessures Active EP1815877B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP06002149A EP1815877B1 (fr) 2006-02-02 2006-02-02 Hydrogel pour le traitment de blessures
AT06002149T ATE449617T1 (de) 2006-02-02 2006-02-02 Hydrogel für wundbehandlung
DE602006010656T DE602006010656D1 (de) 2006-02-02 2006-02-02 Hydrogel für Wundbehandlung
US12/278,036 US20090022780A1 (en) 2006-02-02 2007-01-31 Hydrogel
PCT/EP2007/000824 WO2007088038A1 (fr) 2006-02-02 2007-01-31 Hydrogel
AU2007211617A AU2007211617B2 (en) 2006-02-02 2007-01-31 Hydrogel
CA2640267A CA2640267C (fr) 2006-02-02 2007-01-31 Hydrogel
JP2008552738A JP5294876B2 (ja) 2006-02-02 2007-01-31 ハイドロゲル
IL192908A IL192908A (en) 2006-02-02 2008-07-17 Hydrogel
US13/733,829 US20130122084A1 (en) 2006-02-02 2013-01-03 Hydrogel
US14/057,995 US9415133B2 (en) 2006-02-02 2013-10-18 Hydrogel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06002149A EP1815877B1 (fr) 2006-02-02 2006-02-02 Hydrogel pour le traitment de blessures

Publications (2)

Publication Number Publication Date
EP1815877A1 EP1815877A1 (fr) 2007-08-08
EP1815877B1 true EP1815877B1 (fr) 2009-11-25

Family

ID=37085744

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06002149A Active EP1815877B1 (fr) 2006-02-02 2006-02-02 Hydrogel pour le traitment de blessures

Country Status (9)

Country Link
US (3) US20090022780A1 (fr)
EP (1) EP1815877B1 (fr)
JP (1) JP5294876B2 (fr)
AT (1) ATE449617T1 (fr)
AU (1) AU2007211617B2 (fr)
CA (1) CA2640267C (fr)
DE (1) DE602006010656D1 (fr)
IL (1) IL192908A (fr)
WO (1) WO2007088038A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828358B2 (en) * 2008-03-11 2014-09-09 Materials Modifications, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide
US8852558B2 (en) 2008-03-11 2014-10-07 Materials Modification, Inc. In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst
JP5641634B2 (ja) 2008-03-13 2014-12-17 日東電工株式会社 粘着剤組成物、粘着剤層、粘着部材および画像表示装置、並びに画像表示装置からの光学フィルムの剥離方法および表示パネルの取り出し方法
CZ303548B6 (cs) 2011-01-05 2012-11-28 Contipro Pharma A.S. Zdravotní prípravek tvorící jód, zpusob jeho prípravy a bandáž, která jej obsahuje
JP6182294B2 (ja) * 2011-01-28 2017-08-16 宣政 奥田 殺菌組成物及び医薬
US9290618B2 (en) 2011-08-05 2016-03-22 Sabic Global Technologies B.V. Polycarbonate compositions having enhanced optical properties, methods of making and articles comprising the polycarbonate compositions
EP2741788A4 (fr) 2011-08-14 2015-03-25 Materials Modification Inc Procédé et composition pour la formation in situ d'un blocage artificiel pour supprimer une perte de sang
KR20130035362A (ko) * 2011-09-30 2013-04-09 추봉세 이수 특성에 따른 피부 보습 및 피부 탄력 증진용 하이드로 겔 조성물
RU2485938C1 (ru) * 2011-10-25 2013-06-27 Григорий Константинович Ивахнюк Гель-основа для ранозаживляющих и косметических средств и способ его получения
CN104205376B (zh) 2012-02-03 2018-04-27 沙特基础全球技术有限公司 发光二极管器件及用于生产其的包括转换材料化学的方法
WO2013130606A2 (fr) 2012-02-29 2013-09-06 Sabic Innovative Plastics Ip B.V. Polycarbonate à base de bisphénol a à faible teneur en soufre et contenant un produit chimique à base de matériaux de conversion, et articles fabriqués à partir de celui-ci
US9346949B2 (en) 2013-02-12 2016-05-24 Sabic Global Technologies B.V. High reflectance polycarbonate
WO2014066784A1 (fr) 2012-10-25 2014-05-01 Sabic Innovative Plastics Ip B.V. Dispositifs à diode électroluminescente, leurs procédés de fabrication et leurs utilisations
WO2014186548A1 (fr) 2013-05-16 2014-11-20 Sabic Innovative Plastics Ip B.V. Compositions de polycarbonate ramifié présentant des propriétés chimiques d'un matériau de conversion, et articles associés
US9772086B2 (en) 2013-05-29 2017-09-26 Sabic Innovative Plastics Ip B.V. Illuminating devices with color stable thermoplastic light transmitting articles
US20150150908A1 (en) * 2013-12-03 2015-06-04 Team Unlimited, LLC Compositions and methods for treating skin wounds
CZ2018428A3 (cs) * 2018-08-23 2019-12-04 Contipro As Kompozice obsahující jodid a derivát kyseliny hyaluronové s oxidačním účinkem, způsob její přípravy a použití
CN110859989B (zh) * 2019-10-25 2021-06-22 天津冠勤医药科技有限公司 一种液体创可贴及其制备方法
CN111419799A (zh) * 2020-05-19 2020-07-17 贵州扬生医用器材有限公司 一种脂质体消毒凝胶及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588400A (en) * 1982-12-16 1986-05-13 Johnson & Johnson Products, Inc. Liquid loaded pad for medical applications
JPH07508027A (ja) * 1992-05-12 1995-09-07 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 化粧品及びパーソナルケア製品におけるポリマー
US5902600A (en) * 1992-12-21 1999-05-11 Healthpoint, Ltd. Hydrogel polymer wound dressing
DE9312509U1 (de) * 1993-08-20 1993-10-28 Euro-Celtique S.A., Luxemburg/Luxembourg Präparate zur äußeren Verabreichung von antiseptischen und/oder die Wundheilung fördernden Wirkstoffen
CA2201358C (fr) * 1994-09-30 2004-06-08 Jurgen Regenold Composition pharmaceutique
AU6679400A (en) * 1999-08-27 2001-03-26 Department Of National Defence Hydrogel wound dressing containing liposome-encapsulated therapeutic agent
DE19958458A1 (de) * 1999-12-03 2001-06-21 Beiersdorf Ag Antimikrobiell ausgerüstete Wundauflagen
US6592860B1 (en) * 2000-05-30 2003-07-15 Soluble Systems, Llc Composition and applicator for topical substance delivery
AU2001285286A1 (en) * 2000-08-29 2002-03-13 Noveon Ip Holdings Corp. Hydrogels containing substances
US20030211137A1 (en) * 2001-02-21 2003-11-13 David Sierra Foam-forming wound dressing
EP1390085B1 (fr) * 2001-05-01 2009-08-05 A.V. Topchiev Institute of Petrochemical Synthesis Compositions d'hydrogel
US20030203013A1 (en) * 2002-04-26 2003-10-30 Xylos Corporation Microbial cellulose wound dressing for treating chronic wounds
MY144738A (en) * 2002-07-26 2011-10-31 Malaysian Inst For Nuclear Technology Res Mint Starch hydrogels
CA2499014A1 (fr) * 2002-09-16 2004-03-25 Agennix Incorporated Compositions de lactoferrine et methodes de traitement des plaies
EP1449520A1 (fr) * 2003-02-24 2004-08-25 Euro-Celtique S.A. Utilisation d'iode PVP pour le traitement de l'herpes
JP4818575B2 (ja) * 2003-06-30 2011-11-16 ライオン株式会社 外用貼付剤及び放射線照射外用貼付剤の変色防止方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Römpp Chemie Lexikon CD Version 1.0 - Vitamine", 1995, GEORG THIEME VERLAG, STUTTGART *
"Römpp Chemie Lexikon, CD Version 1.0 - FIlmbildner", GEORG THIEME VERLAG, STUTTGART *
"The United States Pharmacopeia, USP30, Volume 1", 1 May 2007, THE UNITED STATES PHARMACOPEIAL CONVENTION, ROCKVILLE, MD 20852 *

Also Published As

Publication number Publication date
US20140141063A1 (en) 2014-05-22
US20090022780A1 (en) 2009-01-22
US20130122084A1 (en) 2013-05-16
WO2007088038A1 (fr) 2007-08-09
JP5294876B2 (ja) 2013-09-18
CA2640267A1 (fr) 2007-08-09
IL192908A (en) 2012-08-30
ATE449617T1 (de) 2009-12-15
AU2007211617B2 (en) 2010-08-12
AU2007211617A1 (en) 2007-08-09
CA2640267C (fr) 2011-11-29
US9415133B2 (en) 2016-08-16
IL192908A0 (en) 2009-02-11
EP1815877A1 (fr) 2007-08-08
DE602006010656D1 (de) 2010-01-07
AU2007211617A8 (en) 2008-07-24
JP2009525295A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
EP1815877B1 (fr) Hydrogel pour le traitment de blessures
EP1283724B1 (fr) Systemes et methodes de traitement topique avec de l'oxyde nitrique
JP5489171B2 (ja) 皮膚包帯材に関する改良
EP0747062B1 (fr) Complexes stables de polyvinylpyrrolidone et de iode, méthode de préparation
US20020119205A1 (en) Ionic chitosan -iodine complexes : antiseptic hydrogels and wound healing promoters
CN110859989B (zh) 一种液体创可贴及其制备方法
WO2013029525A1 (fr) Composition pharmaceutique comprenant un polymère iodé et un glucocorticostéroïde pour le traitement de la dermatite
EP0716098B1 (fr) Pansement
CN109662942A (zh) 一种抗菌温敏型凝胶剂及其制备方法
CN111135115B (zh) 含炉甘石的组合物
CN115624647B (zh) 一种复合创口愈合药物与膜精华液的生物膜医用敷料及其制备方法和应用
WO2023206055A1 (fr) Modification et utilisation de fibroïne de soie
WO2022126628A1 (fr) Bandage adhésif liquide et son procédé de préparation
WO2016190772A1 (fr) Gel-base pour produits pharmaceutiques et cosmétiques
RU2348400C1 (ru) Фармацевтический препарат для местного и наружного применения на основе низкомолекулярного индуктора интерферона
JPS63160661A (ja) 外用組成物
CN1092050C (zh) 混合型聚维酮碘消毒剂及其制备方法
CN108498852A (zh) Ag/SiO2水凝胶复合海绵的伤口敷料及其制备方法
CN104922053A (zh) 一种壳聚糖纳米微粒喷膜剂的制备方法
CN110812471A (zh) 一种用于创面抗菌复合凝胶
CN114259503A (zh) 一种人用聚维酮碘溶液及其制备方法
CZ279665B6 (cs) Přípravek k ošetření ran

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AXX Extension fees paid

Extension state: AL

Payment date: 20060202

Extension state: MK

Payment date: 20060202

Extension state: BA

Payment date: 20060202

Extension state: YU

Payment date: 20060202

Extension state: HR

Payment date: 20060202

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EURO-CELTIQUE S.A.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAC Information related to communication of intention to grant a patent modified

Free format text: ORIGINAL CODE: EPIDOSCIGR1

RTI1 Title (correction)

Free format text: HYDROGEL FOR THE TREATMENT OF WOUNDS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602006010656

Country of ref document: DE

Date of ref document: 20100107

Kind code of ref document: P

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20091125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100325

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100225

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100308

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100301

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100228

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100226

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100228

26N No opposition filed

Effective date: 20100826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100526

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091125

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006010656

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELL, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006010656

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006010656

Country of ref document: DE

Owner name: EURO-CELTIQUE S.A., LU

Free format text: FORMER OWNER: EURO-CELTIQUE S.A., LUXEMBOURG, LU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006010656

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELL, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006010656

Country of ref document: DE

Owner name: EURO-CELTIQUE S.A., LU

Free format text: FORMER OWNER: EURO-CELTIQUE S.A., LUXEMBURG, LU

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006010656

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20180221

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180227

Year of fee payment: 13

Ref country code: GB

Payment date: 20180221

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180226

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006010656

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20190301

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190903

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190202

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228